Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

References

• Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13:504–10
   Google Scholar
• McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501–10
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. New Engl J Med 1989;321:158–63
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(1 Suppl 1):S182–S238
   Google Scholar
• The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18:50–9
   PubMed Web of Science ®Google Scholar
• Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;61:392–405
   PubMed Web of Science ®Google Scholar
• Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307–12
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176–85
   PubMed Web of Science ®Google Scholar
• Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348–55
   PubMed Web of Science ®Google Scholar
• Ortho Biotech Products, L.P. Procrit® (epoetin alfa) full prescribing information. Available at http://www.procritline.com/common/prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf [accessed February 16, 2006]
   Google Scholar
• Amgen Inc. Aranesp® (darbepoetin alfa) For Injection. Available at: http://www.aranesp.com/pdf/aranesp_PI.pdf [accessed February 16, 2006]
   Google Scholar
• Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 2005;20:2146–52
   PubMed Web of Science ®Google Scholar
• Provenzano R, Bhaduri S, Singh A for the PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;64:113–23
   Google Scholar
• Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23:106–11
   PubMed Web of Science ®Google Scholar
• Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453–60
   PubMed Web of Science ®Google Scholar
• Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327–34
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139: 137–47
   PubMed Web of Science ®Google Scholar
• Medi-Span Drug Data Base, Wolters Kluwer Health. May 2005. Indianapolis, IN
   Google Scholar
• Department of Veteran’s Affairs, Pharmacy Benefits Management Strategic Healthcare Group. Drugs and pharmaceutical prices. Available at: http://www.pbm.va.gov/PBM/prices.htm [accessed February 3, 2006]
   Google Scholar
• Waltzman R, Croot C, Williams D. Randomized comparison of epoetin alfa (40 000 U weekly) and darbepoetin alfa 200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. The Oncologist 2005;10: 642–50
   Google Scholar
• McKenzie RS, Mark TL, Fastenau JM, et al. Clinical and economic benefits of early hemoglobin response in chemo-therapy-related anemia. Presented at the American Society of Health-System Pharmacists 39th Midyear Clinical Meeting and Exhibits; December 5–9, 2004; Orlando, FL
   Google Scholar
• Decter A, Mody SH, Little J, et al. A cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Presented at the 2004 Annual Meeting of the American College of Clinical Pharmacy; October 24–27, 2004; Dallas, TX [abstract 243]
   Google Scholar
• Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381–95
   PubMed Web of Science ®Google Scholar
• Locatelli F, Olivares J, Walker R, et al. on behalf of the European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741–7
   Google Scholar
• Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110–8
   PubMed Web of Science ®Google Scholar
• Anon. 2003 Medicare hospital outpatient prospective payment system final rule. Federal Register 2002;67:66757–9
   Google Scholar
• Federal Register: June 25, 2004 . Department of Health and Human Services Centers for Medicare & Medicaid Services [CMS-9022-N]. From the Federal Register found on www.cms.gov (epoetin alfa search) (from November 15, 2004): http://www.cms.hhs.gov/providerupdate/regs/cms1427fc_3.pdf
   Google Scholar